Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection

Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Folia Medica 2016-03, Vol.58 (1), p.28-35
Hauptverfasser: Burnusuzov, Hasan A, Spasova, Mariya I, Murdjeva, Mariana A, Stoyanova, Angelina A, Mumdziev, Ivan N, Kaleva, Valeriya I, Belcheva, Milena I, Bosheva, Miroslava N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 35
container_issue 1
container_start_page 28
container_title Folia Medica
container_volume 58
creator Burnusuzov, Hasan A
Spasova, Mariya I
Murdjeva, Mariana A
Stoyanova, Angelina A
Mumdziev, Ivan N
Kaleva, Valeriya I
Belcheva, Milena I
Bosheva, Miroslava N
description Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual disease (MRD), are PCR and flow cytometry (FCM). Immunophenotypic modulation (IM) is a well known factor that can hamper the accurate FCM analysis. To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection. Between 2010 and 2012 we prospectively followed up the MRD on days 15 and 33 of induction treatment in bone marrow (BM) samples and on day 8 in peripheral blood (PB). The IM was assessed by comparative analyses of the changes in the mean fluorescence intensity of 7 highly relevant antigens expressed by the leukemic cells and normal B-lymphocytes. IM occurred, to different extents, in all analyzed day 15 BM and in most day 33 BM samples. Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20. No changes in the expression of CD38, CD58 and CD45 were noticed. Measuring the MRD by standardized 8-color flow cytometry helps improve the monitoring of the disease, leading to better therapeutic results. However, the IM of the different antigens expressed by the leukemic blasts should be taken into consideration and cautiously analyzed.
doi_str_mv 10.1515/folmed-2016-0004
format Article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_proquest_miscellaneous_1802743270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b0eb00d556784be990e5d17c569ca059</doaj_id><sourcerecordid>1802743270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4048-64e49f52ca3b12827acf6389fbd95d99ebe6afe679eaf2a8c62510cf495fdb4b3</originalsourceid><addsrcrecordid>eNpdkTuP1DAUhSMEYoeFngpZoqEJXL-SuFxmeYw0KyQEteXY18RDEoc4KUb8eRxml4LKV_Z3jo7vKYqXFN5SSeU7H_sBXcmAViUAiEfFjnIqSkYFf1zsgIEoGxD8qniW0gmgkgDyaXHFat7wppa74vdhGNYxTh2OcTlPwZK76NbeLCGOJHqydEje9yYtZI99n0gYyb4LvetidOTGrguS43mYuthuUJYfcf2JQzDkLoxhMD35iim4NQ-3IaFJSG5xQbv5Py-eeNMnfHF_XhffP374tv9cHr98OuxvjqUVIJqyEiiUl8wa3lLWsNpYX_FG-dYp6ZTCFivjsaoVGs9MYysmKVgvlPSuFS2_Lg4XXxfNSU9zjjWfdTRB_72I8w9t5py9R90CtgBOyqpuRItKAUpHaysrZQ1Ilb3eXLymOf5aMS16CMnm1ZgR45o0bYDVgrMaMvr6P_QU13nMP80U55QLVleZggtl55jSjP5fQAp6K1lfStZbyXorOUte3Ruv7fbyIHholf8B3Ieklg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1833134276</pqid></control><display><type>article</type><title>Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Burnusuzov, Hasan A ; Spasova, Mariya I ; Murdjeva, Mariana A ; Stoyanova, Angelina A ; Mumdziev, Ivan N ; Kaleva, Valeriya I ; Belcheva, Milena I ; Bosheva, Miroslava N</creator><creatorcontrib>Burnusuzov, Hasan A ; Spasova, Mariya I ; Murdjeva, Mariana A ; Stoyanova, Angelina A ; Mumdziev, Ivan N ; Kaleva, Valeriya I ; Belcheva, Milena I ; Bosheva, Miroslava N</creatorcontrib><description>Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual disease (MRD), are PCR and flow cytometry (FCM). Immunophenotypic modulation (IM) is a well known factor that can hamper the accurate FCM analysis. To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection. Between 2010 and 2012 we prospectively followed up the MRD on days 15 and 33 of induction treatment in bone marrow (BM) samples and on day 8 in peripheral blood (PB). The IM was assessed by comparative analyses of the changes in the mean fluorescence intensity of 7 highly relevant antigens expressed by the leukemic cells and normal B-lymphocytes. IM occurred, to different extents, in all analyzed day 15 BM and in most day 33 BM samples. Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20. No changes in the expression of CD38, CD58 and CD45 were noticed. Measuring the MRD by standardized 8-color flow cytometry helps improve the monitoring of the disease, leading to better therapeutic results. However, the IM of the different antigens expressed by the leukemic blasts should be taken into consideration and cautiously analyzed.</description><identifier>ISSN: 0204-8043</identifier><identifier>ISSN: 1314-2143</identifier><identifier>EISSN: 1314-2143</identifier><identifier>DOI: 10.1515/folmed-2016-0004</identifier><identifier>PMID: 27383875</identifier><language>eng</language><publisher>Bulgaria: MEDICAL UNIVERSITY- PLOVDIV</publisher><subject>Adolescent ; ADP-ribosyl Cyclase 1 - immunology ; Antigens, CD19 - immunology ; Antigens, CD20 - immunology ; Antigens, CD34 - immunology ; B-Lymphocytes - immunology ; Bone Marrow ; Bone Marrow Cells - immunology ; CD58 Antigens - immunology ; Child ; Child, Preschool ; childhood ALL ; Female ; Flow Cytometry ; Humans ; immunophenotypic modulation ; Immunophenotyping ; Induction Chemotherapy ; Infant ; Leukocyte Common Antigens - immunology ; Male ; Membrane Glycoproteins - immunology ; MRD ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - immunology ; Neprilysin - immunology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology ; Prospective Studies</subject><ispartof>Folia Medica, 2016-03, Vol.58 (1), p.28-35</ispartof><rights>Copyright MEDICAL UNIVERSITY- PLOVDIV 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4048-64e49f52ca3b12827acf6389fbd95d99ebe6afe679eaf2a8c62510cf495fdb4b3</citedby><cites>FETCH-LOGICAL-c4048-64e49f52ca3b12827acf6389fbd95d99ebe6afe679eaf2a8c62510cf495fdb4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27383875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burnusuzov, Hasan A</creatorcontrib><creatorcontrib>Spasova, Mariya I</creatorcontrib><creatorcontrib>Murdjeva, Mariana A</creatorcontrib><creatorcontrib>Stoyanova, Angelina A</creatorcontrib><creatorcontrib>Mumdziev, Ivan N</creatorcontrib><creatorcontrib>Kaleva, Valeriya I</creatorcontrib><creatorcontrib>Belcheva, Milena I</creatorcontrib><creatorcontrib>Bosheva, Miroslava N</creatorcontrib><title>Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection</title><title>Folia Medica</title><addtitle>Folia Med (Plovdiv)</addtitle><description>Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual disease (MRD), are PCR and flow cytometry (FCM). Immunophenotypic modulation (IM) is a well known factor that can hamper the accurate FCM analysis. To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection. Between 2010 and 2012 we prospectively followed up the MRD on days 15 and 33 of induction treatment in bone marrow (BM) samples and on day 8 in peripheral blood (PB). The IM was assessed by comparative analyses of the changes in the mean fluorescence intensity of 7 highly relevant antigens expressed by the leukemic cells and normal B-lymphocytes. IM occurred, to different extents, in all analyzed day 15 BM and in most day 33 BM samples. Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20. No changes in the expression of CD38, CD58 and CD45 were noticed. Measuring the MRD by standardized 8-color flow cytometry helps improve the monitoring of the disease, leading to better therapeutic results. However, the IM of the different antigens expressed by the leukemic blasts should be taken into consideration and cautiously analyzed.</description><subject>Adolescent</subject><subject>ADP-ribosyl Cyclase 1 - immunology</subject><subject>Antigens, CD19 - immunology</subject><subject>Antigens, CD20 - immunology</subject><subject>Antigens, CD34 - immunology</subject><subject>B-Lymphocytes - immunology</subject><subject>Bone Marrow</subject><subject>Bone Marrow Cells - immunology</subject><subject>CD58 Antigens - immunology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>childhood ALL</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>immunophenotypic modulation</subject><subject>Immunophenotyping</subject><subject>Induction Chemotherapy</subject><subject>Infant</subject><subject>Leukocyte Common Antigens - immunology</subject><subject>Male</subject><subject>Membrane Glycoproteins - immunology</subject><subject>MRD</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - immunology</subject><subject>Neprilysin - immunology</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology</subject><subject>Prospective Studies</subject><issn>0204-8043</issn><issn>1314-2143</issn><issn>1314-2143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DOA</sourceid><recordid>eNpdkTuP1DAUhSMEYoeFngpZoqEJXL-SuFxmeYw0KyQEteXY18RDEoc4KUb8eRxml4LKV_Z3jo7vKYqXFN5SSeU7H_sBXcmAViUAiEfFjnIqSkYFf1zsgIEoGxD8qniW0gmgkgDyaXHFat7wppa74vdhGNYxTh2OcTlPwZK76NbeLCGOJHqydEje9yYtZI99n0gYyb4LvetidOTGrguS43mYuthuUJYfcf2JQzDkLoxhMD35iim4NQ-3IaFJSG5xQbv5Py-eeNMnfHF_XhffP374tv9cHr98OuxvjqUVIJqyEiiUl8wa3lLWsNpYX_FG-dYp6ZTCFivjsaoVGs9MYysmKVgvlPSuFS2_Lg4XXxfNSU9zjjWfdTRB_72I8w9t5py9R90CtgBOyqpuRItKAUpHaysrZQ1Ilb3eXLymOf5aMS16CMnm1ZgR45o0bYDVgrMaMvr6P_QU13nMP80U55QLVleZggtl55jSjP5fQAp6K1lfStZbyXorOUte3Ruv7fbyIHholf8B3Ieklg</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Burnusuzov, Hasan A</creator><creator>Spasova, Mariya I</creator><creator>Murdjeva, Mariana A</creator><creator>Stoyanova, Angelina A</creator><creator>Mumdziev, Ivan N</creator><creator>Kaleva, Valeriya I</creator><creator>Belcheva, Milena I</creator><creator>Bosheva, Miroslava N</creator><general>MEDICAL UNIVERSITY- PLOVDIV</general><general>Pensoft Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20160301</creationdate><title>Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection</title><author>Burnusuzov, Hasan A ; Spasova, Mariya I ; Murdjeva, Mariana A ; Stoyanova, Angelina A ; Mumdziev, Ivan N ; Kaleva, Valeriya I ; Belcheva, Milena I ; Bosheva, Miroslava N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4048-64e49f52ca3b12827acf6389fbd95d99ebe6afe679eaf2a8c62510cf495fdb4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>ADP-ribosyl Cyclase 1 - immunology</topic><topic>Antigens, CD19 - immunology</topic><topic>Antigens, CD20 - immunology</topic><topic>Antigens, CD34 - immunology</topic><topic>B-Lymphocytes - immunology</topic><topic>Bone Marrow</topic><topic>Bone Marrow Cells - immunology</topic><topic>CD58 Antigens - immunology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>childhood ALL</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>immunophenotypic modulation</topic><topic>Immunophenotyping</topic><topic>Induction Chemotherapy</topic><topic>Infant</topic><topic>Leukocyte Common Antigens - immunology</topic><topic>Male</topic><topic>Membrane Glycoproteins - immunology</topic><topic>MRD</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - immunology</topic><topic>Neprilysin - immunology</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology</topic><topic>Prospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burnusuzov, Hasan A</creatorcontrib><creatorcontrib>Spasova, Mariya I</creatorcontrib><creatorcontrib>Murdjeva, Mariana A</creatorcontrib><creatorcontrib>Stoyanova, Angelina A</creatorcontrib><creatorcontrib>Mumdziev, Ivan N</creatorcontrib><creatorcontrib>Kaleva, Valeriya I</creatorcontrib><creatorcontrib>Belcheva, Milena I</creatorcontrib><creatorcontrib>Bosheva, Miroslava N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Folia Medica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burnusuzov, Hasan A</au><au>Spasova, Mariya I</au><au>Murdjeva, Mariana A</au><au>Stoyanova, Angelina A</au><au>Mumdziev, Ivan N</au><au>Kaleva, Valeriya I</au><au>Belcheva, Milena I</au><au>Bosheva, Miroslava N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection</atitle><jtitle>Folia Medica</jtitle><addtitle>Folia Med (Plovdiv)</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>58</volume><issue>1</issue><spage>28</spage><epage>35</epage><pages>28-35</pages><issn>0204-8043</issn><issn>1314-2143</issn><eissn>1314-2143</eissn><abstract>Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual disease (MRD), are PCR and flow cytometry (FCM). Immunophenotypic modulation (IM) is a well known factor that can hamper the accurate FCM analysis. To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection. Between 2010 and 2012 we prospectively followed up the MRD on days 15 and 33 of induction treatment in bone marrow (BM) samples and on day 8 in peripheral blood (PB). The IM was assessed by comparative analyses of the changes in the mean fluorescence intensity of 7 highly relevant antigens expressed by the leukemic cells and normal B-lymphocytes. IM occurred, to different extents, in all analyzed day 15 BM and in most day 33 BM samples. Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20. No changes in the expression of CD38, CD58 and CD45 were noticed. Measuring the MRD by standardized 8-color flow cytometry helps improve the monitoring of the disease, leading to better therapeutic results. However, the IM of the different antigens expressed by the leukemic blasts should be taken into consideration and cautiously analyzed.</abstract><cop>Bulgaria</cop><pub>MEDICAL UNIVERSITY- PLOVDIV</pub><pmid>27383875</pmid><doi>10.1515/folmed-2016-0004</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0204-8043
ispartof Folia Medica, 2016-03, Vol.58 (1), p.28-35
issn 0204-8043
1314-2143
1314-2143
language eng
recordid cdi_proquest_miscellaneous_1802743270
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adolescent
ADP-ribosyl Cyclase 1 - immunology
Antigens, CD19 - immunology
Antigens, CD20 - immunology
Antigens, CD34 - immunology
B-Lymphocytes - immunology
Bone Marrow
Bone Marrow Cells - immunology
CD58 Antigens - immunology
Child
Child, Preschool
childhood ALL
Female
Flow Cytometry
Humans
immunophenotypic modulation
Immunophenotyping
Induction Chemotherapy
Infant
Leukocyte Common Antigens - immunology
Male
Membrane Glycoproteins - immunology
MRD
Neoplasm, Residual - diagnosis
Neoplasm, Residual - drug therapy
Neoplasm, Residual - immunology
Neprilysin - immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology
Prospective Studies
title Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A47%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunophenotypic%20Modulation%20of%20the%20Blast%20Cells%20in%20Childhood%20Acute%20Lymphoblastic%20Leukemia%20Minimal%20Residual%20Disease%20Detection&rft.jtitle=Folia%20Medica&rft.au=Burnusuzov,%20Hasan%20A&rft.date=2016-03-01&rft.volume=58&rft.issue=1&rft.spage=28&rft.epage=35&rft.pages=28-35&rft.issn=0204-8043&rft.eissn=1314-2143&rft_id=info:doi/10.1515/folmed-2016-0004&rft_dat=%3Cproquest_doaj_%3E1802743270%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1833134276&rft_id=info:pmid/27383875&rft_doaj_id=oai_doaj_org_article_b0eb00d556784be990e5d17c569ca059&rfr_iscdi=true